文献速递心力衰竭与心肌病

KCCQ-12 预测心衰结局:真实世界验证

Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

本研究在2019年7月至2024年3月的心衰门诊队列中,对4406例被分配KCCQ-12的患者进行真实世界验证。KCCQ-OS评分<25者90天住院(OR 3.49)和累积死亡(HR 3.09)风险显著高于评分≥75者,且KCCQ-OS是机器学习模型中最重要的预测特征。未完成KCCQ-12本身也与更差结局独立相关。

要点

  • KCCQ-OS评分<25与90天住院和累积死亡风险显著升高相关。
  • KCCQ-OS是预测90天住院和累积死亡的最重要特征。
  • 未完成KCCQ-12评估本身与更差的90天住院和1年死亡独立相关。

核心结论

  • 在心衰门诊真实世界实践中,较低的KCCQ-OS评分与住院和死亡风险增加强烈相关,评分<25者风险最高。
  • 未完成KCCQ-12本身与更差结局独立相关。
  • KCCQ-OS是机器学习模型中90天住院和累积死亡的主要预测因子,支持KCCQ-12作为常规临床预后工具。

研究设计与样本

  • 队列研究,纳入2019年7月至2024年3月心衰门诊被分配KCCQ-12的患者共4406例。
  • 其中2888例(66%)完成至少1份问卷,中位KCCQ-OS评分为59.4(Q1-Q3:35.4-81.8)。
  • 主要暴露为KCCQ-12 Overall Summary(KCCQ-OS)评分,主要结局为90天住院和累积死亡。
  • 采用多变量校正逻辑回归和Cox比例风险模型评估关联,并使用梯度提升(XGBoost)和随机生存森林机器学习模型评估KCCQ-OS特征重要性。

主要发现

  • 与KCCQ-OS评分≥75者相比,评分<25者90天住院校正OR为3.49(95%CI:2.50-4.90),累积死亡校正HR为3.09(95%CI:2.29-4.17)。
  • XGBoost模型中KCCQ-OS是预测90天住院的最重要特征,AUC为0.760(95%CI:0.706-0.811)。
  • 随机生存森林模型中KCCQ-OS是预测累积死亡的最重要特征,C-index为0.783(95%CI:0.742-0.824)。
  • 校正主要分析中所有变量后,未完成KCCQ-12与90天住院(OR 1.72;95%CI:1.46-2.02)和1年死亡(HR 1.52;95%CI:1.25-1.84)独立相关。

临床怎么用

  • 在心衰门诊常规收集KCCQ-12,利用KCCQ-OS评分识别90天住院和死亡高风险患者。
  • KCCQ-OS评分<25提示风险显著升高,可考虑加强随访和干预。
  • 患者未完成KCCQ-12评估本身应视为风险标志,需关注其临床状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12), a patient-reported outcome measure for adults with heart failure, is associated with hospitalizations and mortality in clinical trials. Curated data sets from controlled trials differ substantially from pragmatic data collected from real-world settings, however, and few data exist on the KCCQ-12's predictive utility in clinical practice. OBJECTIVES: This study sought to evaluate the predictive utility of the KCCQ-12 for hospitalizations and mortality when administered during outpatient heart failure care. METHODS: We conducted a cohort study of patients assigned the KCCQ-12 in heart failure clinics from July 2019 through March 2024. The primary exposure was KCCQ-12 Overall Summary (KCCQ-OS) score. The primary outcomes were 90-day hospitalization and cumulative mortality. Multivariable-adjusted associations were assessed using logistic regression and Cox proportional hazards models. Gradient boosting (XGBoost) and random survival forest machine learning models were used to evaluate KCCQ-OS feature importance in predicting 90-day hospitalizations and cumulative mortality, respectively. RESULTS: Among 4,406 patients assigned the KCCQ-12, 2,888 (66%) completed at least 1 questionnaire. The median KCCQ-OS score was 59.4 (Q1-Q3: 35.4-81.8). Patients with KCCQ-OS scores <25 had higher adjusted risks of 90-day hospitalization (OR: 3.49; 95% CI: 2.50-4.90) and cumulative mortality (HR: 3.09; 95% CI: 2.29-4.17) compared with those with scores ≥75. The KCCQ-OS score was the most important feature for predicting 90-day hospitalizations in the XGBoost model (area under the receiver-operating characteristic curve: 0.760; 95% CI: 0.706-0.811) and the most important feature for predicting cumulative mortality in the random survival forest model (C-index 0.783; 95% CI: 0.742-0.824) compared with other clinical, demographic, and laboratory variables. KCCQ-12 noncompletion was independently associated with increased 90-day hospitalization (OR: 1.72; 95% CI: 1.46-2.02) and 1-year mortality (HR: 1.52; 95% CI: 1.25-1.84) after adjusting for all variables in the primary analysis. CONCLUSIONS: In outpatient heart failure care, lower KCCQ-OS scores were strongly associated with increased hospitalizations and mortality, with the greatest risk among patients with scores <25. Noncompletion of the KCCQ-12 was itself associated with worse outcomes. The KCCQ-OS score was the dominant predictor of 90-day hospitalizations and cumulative mortality in machine learning models, supporting the KCCQ-12 as a prognostic tool in routine clinical practice.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. El-Sabawi, Al-Garadi, Steitz, et al. Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12. J Am Coll Cardiol. 2025. PMID: 40499980. doi:10.1016/j.jacc.2025.03.545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。